Telemedicine can deliver support to patients who are otherwise at high risk for progressive nonadherence to their psychotropic medication regimens.
Data from two Phase 3 studies evaluating brexpiprazole for the treatment of patients with manic episodes associated with bipolar I disorder did not meet the primary endpoint of statistical separation from placebo as measured by the Young Mania Rating Scale at week 3.
Interventions targeting motor activity and energy may be more efficacious than current approaches targeting depressed mood in adults with bipolar disorder.
A combination of sleep deprivation and light therapy may alleviate symptoms in patients experiencing depressive episodes.
Investigators examined the prevalence and impact of comorbid anxiety in patients with bipolar disorder using the Bipolar Inventory of Symptoms Scale.
Investigators sought to identify cognitive subgroups in patients with bipolar disorder, no known neuropsychological performance issues, and no drug or alcohol dependence or abuse issues.
Three classes of drugs hold potential as repurposed agents to treat patients with serious mental illness.
An analysis of once-daily valbenazine trials revealed improvements in tardive dyskinesia in patients with mood disorders.
Sleep has important functions for the regulation of mood and emotion, and treatment of sleep disturbances in bipolar disorder may improve patient outcomes.
Researchers evaluated the relationship between pediatric subthreshold bipolar disorder and significant psychiatric impairments and increased rates of suicidality.